465 related articles for article (PubMed ID: 22634722)
41. Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies.
Tonelli AR; Brantly ML
Ther Adv Respir Dis; 2010 Oct; 4(5):289-312. PubMed ID: 20650978
[TBL] [Abstract][Full Text] [Related]
42. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals.
Hurley K; Lacey N; O'Dwyer CA; Bergin DA; McElvaney OJ; O'Brien ME; McElvaney OF; Reeves EP; McElvaney NG
J Immunol; 2014 Oct; 193(8):3978-91. PubMed ID: 25217166
[TBL] [Abstract][Full Text] [Related]
43. Immune-modulating effects of alpha-1 antitrypsin.
Ehlers MR
Biol Chem; 2014 Oct; 395(10):1187-93. PubMed ID: 24854541
[TBL] [Abstract][Full Text] [Related]
44. α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.
Gottlieb PA; Alkanani AK; Michels AW; Lewis EC; Shapiro L; Dinarello CA; Zipris D
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1418-26. PubMed ID: 24527714
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus.
Park SS; Rodriguez Ortega R; Agudelo CW; Perez Perez J; Perez Gandara B; Garcia-Arcos I; McCarthy C; Geraghty P
Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33923873
[TBL] [Abstract][Full Text] [Related]
46. The BLT1 Inhibitory Function of α-1 Antitrypsin Augmentation Therapy Disrupts Leukotriene B4 Neutrophil Signaling.
O'Dwyer CA; O'Brien ME; Wormald MR; White MM; Banville N; Hurley K; McCarthy C; McElvaney NG; Reeves EP
J Immunol; 2015 Oct; 195(8):3628-41. PubMed ID: 26371243
[TBL] [Abstract][Full Text] [Related]
47. Sex-specific differences in emphysema using a murine antisense oligonucleotide model of α-1 antitrypsin deficiency.
Joshi R; Ojha M; Lewis J; Fan Q; Monia B; Guo S; Varisco BM
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1165-L1173. PubMed ID: 31017014
[TBL] [Abstract][Full Text] [Related]
48. Alpha-1-antitrypsin deficiency: Genetic variations, clinical manifestations and therapeutic interventions.
Hazari YM; Bashir A; Habib M; Bashir S; Habib H; Qasim MA; Shah NN; Haq E; Teckman J; Fazili KM
Mutat Res Rev Mutat Res; 2017 Jul; 773():14-25. PubMed ID: 28927525
[TBL] [Abstract][Full Text] [Related]
49. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
50. Methods of Purification and Application Procedures of Alpha1 Antitrypsin: A Long-Lasting History.
Viglio S; Iadarola P; D'Amato M; Stolk J
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887469
[TBL] [Abstract][Full Text] [Related]
51. Alpha-1 Antitrypsin Deficiency: Beyond the Protease/Antiprotease Paradigm.
Cosio MG; Bazzan E; Rigobello C; Tinè M; Turato G; Baraldo S; Saetta M
Ann Am Thorac Soc; 2016 Aug; 13 Suppl 4():S305-10. PubMed ID: 27564665
[TBL] [Abstract][Full Text] [Related]
52. Alpha-1-antitrypsin inhibits human immunodeficiency virus type 1.
Shapiro L; Pott GB; Ralston AH
FASEB J; 2001 Jan; 15(1):115-122. PubMed ID: 11149899
[TBL] [Abstract][Full Text] [Related]
53. Protease-Specific Biomarkers to Analyse Protease Inhibitors for Emphysema Associated with Alpha 1-Antitrypsin Deficiency. An Overview of Current Approaches.
Viglio S; Bak EG; Schouten IGM; Iadarola P; Stolk J
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33494436
[TBL] [Abstract][Full Text] [Related]
54. Role of alpha-1 antitrypsin in human health and disease.
de Serres F; Blanco I
J Intern Med; 2014 Oct; 276(4):311-35. PubMed ID: 24661570
[TBL] [Abstract][Full Text] [Related]
55. Production and characterization of mono-PEGylated alpha-1 antitrypsin for augmentation therapy.
Liu X; Vanvarenberg K; Kouassi KGW; Mahri S; Vanbever R
Int J Pharm; 2022 Jan; 612():121355. PubMed ID: 34883205
[TBL] [Abstract][Full Text] [Related]
56. α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.
Campos MA; Lascano J
Ther Adv Respir Dis; 2014 Oct; 8(5):150-61. PubMed ID: 25013223
[TBL] [Abstract][Full Text] [Related]
57. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.
Lieberman J
Chest; 2000 Nov; 118(5):1480-5. PubMed ID: 11083705
[TBL] [Abstract][Full Text] [Related]
58. α1-Antitrypsin attenuates acute rejection of orthotopic murine lung allografts.
Nakagiri T; Wrenger S; Sivaraman K; Ius F; Goecke T; Zardo P; Grau V; Welte T; Haverich A; Knöfel AK; Janciauskiene S
Respir Res; 2021 Nov; 22(1):295. PubMed ID: 34789247
[TBL] [Abstract][Full Text] [Related]
59. Alpha-1 Antitrypsin-Deficient Macrophages Have Increased Matriptase-Mediated Proteolytic Activity.
Krotova K; Marek GW; Wang RL; Aslanidi G; Hoffman BE; Khodayari N; Rouhani FN; Brantly ML
Am J Respir Cell Mol Biol; 2017 Aug; 57(2):238-247. PubMed ID: 28362108
[TBL] [Abstract][Full Text] [Related]
60. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency.
Stockley RA; Bayley DL; Unsal I; Dowson LJ
Am J Respir Crit Care Med; 2002 Jun; 165(11):1494-8. PubMed ID: 12045122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
